Ahn M et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;Abstract LBA7.
Besse B et al. Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant advanced NSCLC: An early analysis from the phase III MARIPOSA study. ESMO 2024;Abstract LBA55.
Blakely CM et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: A phase II multicenter study. J Clin Oncol 2024;42(26):3105-14. Abstract
Fang W et al. Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in phase 2 study. AACR 2024;Abstract CT247.
Felip E et al. Amivantamab plus lazertinib vs osimertinib in 1L EGFR-mutant advanced NSCLC with biomarkers of high-risk disease: A secondary analysis from MARIPOSA. Ann Oncol 2024;35(9):805-16. Abstract
Gadgeel S et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: Longer follow-up of the MARIPOSA study. WCLC 2024;Abstract OA02.03.
Garon EB et al. Phase 3 TroFuse-004 study: Sac-TMT vs chemotherapy for previously treated advanced NSCLC with EGFR/other genomic alterations. WCLC 2024;Abstract P2.10A.06.
Jänne PA et al. CNS efficacy of osimertinib with or without CT in EGFR-mutated advanced NSCLC. J Clin Oncol 2024;42(7):808-20. Abstract
John T et al. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). ASCO 2024;Abstract 8005.
Leighl NB et al. Subcutaneous vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated NSCLC: Primary results from phase III PALOMA-3 study. J Clin Oncol 2024;42(30):3593-605. Abstract
Leighl NB et al. Trofuse-009: Phase 3 study of Sac-TNT vs platinum-doublet chemotherapy for previously treated EGFR-mutated advanced NSCLC. WCLC 2024;Abstract P2.10A.07.
Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.
Lu S et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024;391(7):585-97. Abstract
Lu S et al. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: Analyses of central nervous system efficacy and distant progression from the phase III LAURA study. Ann Oncol 2024;35(12):1116-25. Abstract
Mok T et al. HERTHENA-Lung02: Phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol 2024;20(15):969-80. Abstract
Mok T et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: Final results of CheckMate 722. J Clin Oncol 2024;42(11):1252-64. Abstract
Nguyen D et al. Amivantamab plus lazertinib vs osimertinib in first-line, EGFR-mutant advanced NSCLC: Patient-relevant outcomes from MARIPOSA. WCLC 2024;Abstract MA12.07.
Park S et al. Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with EGFR mutation-positive NSCLC (BLOSSOM). J Clin Oncol 2024;42(23):2747-56. Abstract
Passaro A et al. Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab. ESMO 2024;Abstract 1254MO.
Popat S et al. Amivantamab plus CT vs CT in EGFR-mutated, advanced NSCLC after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2. ESMO 2024;Abstract LBA54.
Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025[Online ahead of print]. Abstract
Valdiviezo N et al. FLAURA2: Impact of tumor burden on outcomes of 1L osimertinib ± CT in patients with EGFR-mutated advanced NSCLC. WCLC 2024;Abstract MA12.04.
Yang JC et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor‒resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol 2024;42(34):4029-39. Abstract
Yu HA et al. REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations. ASCO 2024;Abstract TPS8670.
Yu HA et al. REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations. ASCO 2024;Abstract TPS8671.
Yu HA et al. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Ann Oncol 2024;35(5):437-47. Abstract
Yu HA et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol 2023;41(35):5363-75. Abstract